You are using an outdated browser. Please upgrade your browser to improve your experience.

tafasitamab

Ligand Summary
Description
Tafasitamab-cxix is an Fc-modified monoclonal antibody that binds to CD19 antigen expressed on the surface of pre-B and mature B lymphocytes and on several B-cell malignancies, including diffuse large B-cell lymphoma (DLBCL). Upon binding to CD19, tafasitamab-cxix mediates B-cell lysis through apoptosis and immune effector mechanisms, including antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP).
Synonyms & Links
DrugCentral: 5404
LyCHI:  tafasitamab


loading...
Target Activities